GlassScriptPhysician profile
Sameena M Zahoor
NPI 1649242280
$2,369.92
in general payments reported to CMS, 2019-2025
18 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.98 · 2021: $12.37 · 2023: $401 · 2024: $877 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.21 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $453.96 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $339.19 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $245.20 | 2023-2025 | |
| Lilly USA, LLC | $225.63 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.66 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $89.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $86.89 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.26 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $65.16 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $61.55 | 2024-2025 | |
| Astellas Pharma US INC | $43.94 | 2025 | Veozah |
| Alk-Abello, INC | $20.39 | 2024 | Odactra, Grastek, Ragwitek |
| Sanofi Pasteur INC. | $16.57 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.43 | 2024 | Nuzyra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16.33 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.23 | 2025 | Euflexxa |
| Gilead Sciences, INC. | $16.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameena Zahoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.